Eli Lilly (LLY)
(Delayed Data from NYSE)
$764.71 USD
+16.52 (2.21%)
Updated Sep 16, 2025 03:59 PM ET
After-Market: $764.00 -0.71 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Eli Lilly and Company has a PEG ratio of 1.49 compared to the Large Cap Pharmaceuticals industry's PEG ratio of 1.56.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LLY 764.71 +16.52(2.21%)
Will LLY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LLY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LLY
Why the Market Dipped But Eli Lilly (LLY) Gained Today
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
LLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?
Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?
Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?
Other News for LLY
Eli Lilly To Invest $5 Billion In New Virginia Manufacturing Facility To Support Cancer Drugs Manufacturing
Eli Lilly (LLY) Faces Investor Concerns Over Recent Trial Data
Eli Lilly's (LLY) Peresolimab Faces Efficacy Challenges in Rheumatoid Arthritis Treatment
Eli Lilly (LLY) Commits $5B to New Manufacturing Facility in Virginia
AnaptysBio falls after data abstract on Lilly’s peresolimab